Express News | Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With Enhanze® for Multiple Types of Cancer
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With ENHANZE for Multiple Types of Cancer
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Even Though Halozyme Therapeutics (NASDAQ:HALO) Has Lost US$251m Market Cap in Last 7 Days, Shareholders Are Still up 271% Over 5 Years
Why Halozyme Therapeutics (HALO) Is a Top Momentum Stock for the Long-Term